Indeed, α-LGR5-ADCs have been previously road-tested for targeting LoVo CRC cell tumours (Gong et al, 2016; Junttila et al, 2015) as well as an LGR5-expressing ER-PDX tumour model (Hagerling et al, 2020). Here, LGR5 is linked to colorectal carcinoma.